Accelerate cardiac drug development with our comprehensive platform for cardiotoxicity screening, target identification, and predictive safety pharmacology.
From early target identification to clinical candidate selection, our platform supports every stage of cardiac drug development.
Predict cardiac safety liabilities early in development. Our AI models analyze functional endpoints from iPSC-cardiomyocytes to detect arrhythmogenic potential, contractile dysfunction, and structural toxicity before costly clinical failures.
Leverage our cardiac knowledge graph to identify novel drug targets with integrated pathway analysis and disease association mapping.
Automated IC50/EC50 calculations with statistical confidence intervals. Multi-parameter analysis across concentration ranges.
High-throughput ready
SAR analysis tools
Organoid & EHT support
Predictive modeling
Meet regulatory requirements with our integrated safety pharmacology suite designed for CiPA compliance and beyond.
Full hERG, Nav1.5, and Cav1.2 channel assessments with standardized protocols
Proprietary algorithms for proarrhythmic liability prediction based on multi-electrode array data
Automated field potential duration analysis with corrected QT calculations
Video-based contraction analysis for inotropic and lusitropic effects
Mine our cardiac knowledge graph for novel targets. Integrate genomics, proteomics, and literature data.
High-throughput screening with automated phenotypic analysis. AI-powered hit selection.
Multiparametric profiling for SAR analysis. Balance efficacy and safety in real-time.
CiPA-compliant cardiotoxicity screening. Comprehensive risk assessment reporting.
Data-driven decision support for clinical candidate nomination with full audit trails.
Connect your existing infrastructure with our flexible API and data integration capabilities.
Seamlessly connect with your laboratory information management system for automated data import and sample tracking.
Direct integration with major plate readers, imaging systems, and MEA platforms including Axion, Molecular Devices, and more.
Export to your enterprise data lake with full metadata. Support for standard formats including SDF, CSV, and JSON.
Full compliance with electronic records and signatures regulation. Audit trails, access controls, and validation packages.
Comprehensive API for programmatic access. Automate workflows, batch processing, and custom integrations.
Role-based access controls, shared workspaces, and real-time collaboration for distributed research teams.
From early discovery to regulatory submission, Cardiomics.ai supports cardiac safety programs across the drug development lifecycle.
High-throughput screening for drug candidates
Cardiac safety de-risking for novel therapies
Scalable preclinical cardiac services
Research-grade tools for cardiac biology
Start screening compounds today or schedule a demo to see how Cardiomics.ai can transform your cardiac safety program.
Sign in to access your dashboard